Sunday, September 20, 2026

Crescent Capital BDC And 3 Other Stocks Have Very High Payout Ratio

Crescent Capital BDC And 3 Other Stocks Have Very High Payout Ratio

(VIANEWS) - Crescent Capital BDC (CCAP), Global Self Storage (SELF), Gilead Sciences (GILD) are the highest payout ratio stocks on this list.

We have congregated information concerning stocks with the highest payout ratio as yet. The payout ratio in itself isn't a guarantee of good investment but it's an indicator of whether dividends are being paid and how the company chooses to distribute them.

When researching a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.

1. Crescent Capital BDC (CCAP)

328% Payout Ratio

Crescent Capital BDC, Inc. is a business development company. The fund focuses on originating and investing in the debt of middle market companies. It typically focuses on companies based in United States.

Earnings Per Share

As for profitability, Crescent Capital BDC has a trailing twelve months EPS of $0.5.

PE Ratio

Crescent Capital BDC has a trailing twelve months price to earnings ratio of 27.8. Meaning, the purchaser of the share is investing $27.8 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.46%.

Moving Average

Crescent Capital BDC's value is under its 50-day moving average of $14.37 and under its 200-day moving average of $14.90.

Volume

Today's last reported volume for Crescent Capital BDC is 117992 which is 14.6% above its average volume of 102954.

2. Global Self Storage (SELF)

144.74% Payout Ratio

Global Self Storage is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible and secure storage space for residential and commercial customers. Through its wholly owned subsidiaries, the company owns and/or manages 13 self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.

Earnings Per Share

As for profitability, Global Self Storage has a trailing twelve months EPS of $0.19.

PE Ratio

Global Self Storage has a trailing twelve months price to earnings ratio of 26.84. Meaning, the purchaser of the share is investing $26.84 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.31%.

Yearly Top and Bottom Value

Global Self Storage's stock is valued at $5.10 at 20:23 EST, way under its 52-week high of $7.36 and above its 52-week low of $4.75.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Global Self Storage's EBITDA is 59.62.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Mar 13, 2023, the estimated forward annual dividend rate is 0.29 and the estimated forward annual dividend yield is 5.69%.

Moving Average

Global Self Storage's worth is below its 50-day moving average of $5.27 and under its 200-day moving average of $5.34.

3. Gilead Sciences (GILD)

80.22% Payout Ratio

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Earnings Per Share

As for profitability, Gilead Sciences has a trailing twelve months EPS of $4.36.

PE Ratio

Gilead Sciences has a trailing twelve months price to earnings ratio of 18.27. Meaning, the purchaser of the share is investing $18.27 for every dollar of annual earnings.

Previous days news about Gilead Sciences (GILD)

  • According to Business Insider on Wednesday, 3 May, "With this acquisition, Gilead Sciences has enhanced its position in the immuno-oncology market, which is one of the fastest-growing segments of the pharmaceutical industry. ", "The acquisition is expected to enable Gilead Sciences to develop innovative immuno-oncology treatments to help patients suffering from cancer."

4. Standard Register Company (SR)

60.33% Payout Ratio

Spire Inc., together with its subsidiaries, engages in the purchase, retail distribution, and sale of natural gas to residential, commercial, industrial, and other end-users of natural gas in the United States. The company operates through two segments, Gas Utility and Gas Marketing. It is also involved in the marketing of natural gas. In addition, the company engages in the transportation of propane through its propane pipeline; risk management; and other activities. Further, it provides physical natural gas storage services. The company was formerly known as The Laclede Group, Inc. and changed its name to Spire Inc. in April 2016. Spire Inc. was founded in 1857 and is based in Saint Louis, Missouri.

Earnings Per Share

As for profitability, Standard Register Company has a trailing twelve months EPS of $4.6.

PE Ratio

Standard Register Company has a trailing twelve months price to earnings ratio of 15.08. Meaning, the purchaser of the share is investing $15.08 for every dollar of annual earnings.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Standard Register Company's EBITDA is 3.1.

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com